Global Apoptosis Assays Market - 2023-2030

Overview

Apoptosis assay detects and quantifies the cellular events associated with programmed cell death, including caspase activation, cell surface exposure of phosphatidylserine (PS), and DNA fragmentation. Cellular apoptosis assays to detect programmed cell death using Annexin V, Caspase, and TUNEL DNA fragmentation assays.

Cell-based assays detect specific cell death processes across the apoptotic timeline. Apoptosis assay kits and reagents are available for investigations in programmed cell death, a natural part of the cell's life cycle.

Market Dynamics

Increase in the innovative apoptotic assay kits is expected to drive the market growth

Apoptosis Assay Kit is designed to monitor apoptotic, necrotic, and healthy cells simultaneously. Innovative apoptosis kits offer advanced technologies and technological procedures, which reduces the time in research studies. Thus, these factors increase the demand for the kits, which drives the market growth.

For instance, on December 9, 2022, TransGen introduced 4 Annexin V testing kits with different probes and dyes for early apoptosis detection using flow cytometry or fluorescence microscopy. These kits are easy to operate, highly sensitive and specific, and are suitable for detecting early apoptosis of the cells.

Additionally, on September 20, 2022, Nanolive marketed the LIVE Cell Death Assay, a push button, automated solution for profiling cell health, death, apoptosis, and necrosis, label-free. Based on a machine learning (ML) algorithm, it classifies cellular objects completely label-free as living or dead, distinguishing apoptotic and necrotic cells.

Additionally, the increase in novel therapeutics and the increase in the number of cancer research for developing advanced treatments act as driving factors of the market growth.

High investments required in research and development are expected to hamper the market growth

Higher costs of developing a cancer drug can impact the cost of the assays. It is estimated that the average R&D cost per new drug ranges from less than $1 Million to more than $2 Million per drug. For instance, Dinutuximab, a drug used for post-consolidation therapy for childhood-risk neuroblastoma, costs $276 million to develop. Thus, the high cost of developing a drug can affect the market growth.

Segment Analysis

The global apoptosis market is segmented based on product, detection technology, application, end-user, and region.

Flow cytometry holds the largest market share in the global apoptosis assays market

The flow cytometry segment holds a significant position in the apoptosis assay market share due to the efficiency of the technique over the other methods. It is one of the most popular and versatile applications for studying apoptosis. It offers the ability to study large numbers of cells individually rather than in a mixed population, examining simultaneously the expression of many proteins like cell-specific markers and indicators of apoptosis.

It has wide applications in the pharmaceutical industry because it provides a way to understand the drug's mechanism of action in the drug discovery process. To stratify a better target for patients, it is necessary to understand the mechanism of drug action, which flow cytometry does.

On June 3, 2022, BD launched an advanced flow cytometry system that sorts cells based on their inner workings. The new BD FACSDiscover S8 Cell Sorter features the breakthrough BD cell view image technology.

Additionally, it has a variety of applications in research and development. Flow Cytometry detects changes in the plasma and mitochondrial membranes, caspase activity, nuclear condensation, and fragmentation as possible indicators of apoptosis. Flow cytometry allows the study of all aspects of apoptosis, from induction via surface receptors, to late stages where DNA fragmentation occurs. Thus, the above factors allow the usage of a flow cytometer in apoptosis studies. Thus, flow cytometry holds a significant market share.

Geographical Penetration

North America is expected to hold a significant position in the global apoptosis assays market share

An increase in the development of anticancer drugs in the region is expected to hold the region in the dominant market share. Apoptosis assays elucidate the cell death-related events during tumor cell killing by anti-cancer drugs. Apoptosis assays are available for single and multi-time point analysis as well as real-time live-cell imaging. Many anticancer drugs are designed to kill cells by inducing apoptosis.

The increase in the number of cancer cases is influencing the development and launches of new drugs, thus increasing the region's market share. For instance, according to the American Cancer Society, it is estimated that 1.9 million new cancer cases have been diagnosed and 609,360 cancer deaths in the United States in 2022. Thus, increasing the development of drugs for the treatment of cancer.

An increase in the development and approvals of anticancer drugs increases apoptosis studies to evaluate the mechanism of the drug. For instance, on September 2, 2022, the FDA approved durvalumab in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer. Thus, the number of anticancer drug approvals is expected to hold the region in the dominant position in the apoptosis assays market

COVID-19 Impact Analysis

COVID-19 has impacted the growth of the apoptosis assays market. The shift of focus to research and developing novel products for treating COVID-19 has created a negative impact on the apoptosis assays market growth. The delay in approvals of the kits has also affected the market growth. The delay in drug discovery has also impacted the apoptosis assays market.

Market Segmentation

By Product

• Assay Kits
  • Caspase assays
  • DNA Fragmentation Assays
  • Annexin V and Cell Permeability Assays

• Mitochondrial Assays
  • Reagents
  • Microplates

By Detection Technology

• Flow Cytometry
• Cell Imaging and Microscopy
• Spectrophotometry
• Others

By Application

• Drug Discovery and Development
• Clinical and Diagnostic Applications
• Stem Cell Research
• Others

By End-User

• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Competitive Landscape

The global apoptosis assays market is fragmented, with the presence of many local and international players. Thermo Fisher Scientific Inc., Elabscience Biotechnology Inc., Bio-Rad Laboratories, Merck KGaA, Molecular Devices, LLC., Becton, Dickinson, and Company, Bio-Techne Corporation., Promega Corporation., BPS Bioscience Inc., and Agilent Technologies, Inc. are the leading companies with a significant market share.

Why Purchase the Report?

• To visualize the global apoptosis assays market segmentation based on product, detection technology, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of apoptosis assays market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global apoptosis assays market report would provide approximately 59 tables, 70 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies